Key result
GPR174 knockout markedly alleviated Angiotensin II-induced increases in central retinal thickness, vascular permeability, and inflammatory response in mice by inhibiting PI3K/AKT signaling.
Why the study?
The molecular mechanisms controlling hypertensive retinopathy progression and whether GPR174 is involved in Ang II-induced retinopathy remain unclear.
GPR174 suppression attenuates Ang II-induced hypertensive retinopathy by reducing inflammation via the PI3K/AKT signaling pathway, suggesting a potential novel therapeutic target.
Should not change clinical practice for hypertensive retinopathy; hypothesis-generating for GPR174 targeting in preclinical models.
Hypertension is closely associated with eye diseases, including hypertensive retinopathy. However, the molecular mechanism controlling the progression of hypertensive retinopathy remains poorly understood. G-Protein Coupled Receptor 174 (GPR174) is expressed in various tissues, and plays a critical role in regulating immune and inflammatory responses. However, if GPR174 is involved in angiotensin II (Ang II)-induced retinopathy is still unclear. In this study, hypertensive retinopathy was induced by Ang II infusion in the wild type (GPR174+/+) and GPR174 knockout (GPR174−/−) mice. Clinical data indicated that GPR174 levels were markedly up-regulated in serum of patients with hypertension (HP) or hypertensive retinopathy (HR), along with increased trypsin-like activity. Similar changes of GRP174 and trypsin-like activity were observed in Ang II-infused mice. Furthermore, Ang IIsignificantly increased the central retinal thickness, vascular permeability and inflammatory response in GPR174+/+ micewhen compared with the saline GPR174+/+ mice. Of note, these effects were markedly alleviated by the knockout ofGPR174 in Ang II-treated mice. Consistently, vascular endothelial growth factor (VEGF) expression levels in retinal tissue were also stimulated by Ang II, which were clearly attenuated by GPR174−/−. In addition, phosphatidylinositol 3-kinase (PI3 K)/AKT and nuclear factor-κB (NF-κB) signaling pathways were markedly activated in retinas of Ang II-infused GPR174+/+ mice, whereas being greatly ameliorated by GPR174−/−. The in vitro data showed that pre-treatment of PI3 K/AKT specific inhibitor LY294002 remarkably abrogated GPR174 over-expression-accelerated expression levels of Iba-1, tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 in lipopolysaccharide (LPS)-incubated retinal microglial cells.Furthermore, in LPS-exposed retinal microglial cells, PI3 K/AKT and NF-κB pathways were further promoted by GPR174 over-expression, which were significantlyabolished by LY294002. Thus, GPR174 might be a positive meditator of inflammation, contributing to Ang II-induced retinopathy by activating PI3 K/AKT signaling, and could be considered as a novel therapeutic target for the treatment of hypertensive retinopathy.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2019) studied Hypertensive retinopathy. GPR174 knockout vs. Wild type (GPR174+/+) mice was evaluated on Central retinal thickness, vascular permeability and inflammatory response. GPR174 knockout markedly alleviated Angiotensin II-induced increases in central retinal thickness, vascular permeability, and inflammatory response in mice by inhibiting PI3K/AKT signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: